Detection of sentinel lymph node using contrast-enhanced ultrasonography

Development of the method for detection of sentinel lymph node using contrast-enhanced ultrasonography, and evaluation of its metastasis with vascular Imaging in oral and oropharyngeal cancers - Sentinel lymph node detection with contrast-enhanced ultrasonography, and its evaluation of metastasis with vascular imaging

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180002

Enrollment

Registered

2018-08-21

Start date

2019-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral cancer and Oropharyngeal cancer Other cancer

Interventions

Local injections of Sonazoid and Indigo carmine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients of oral or oropharyngeal cancer with clinical cN0 disease using neck computed tomography 2) Patients without the histories of previous treatment for oral or oropharyngeal cancer 3) Age, at the time of the consent, is 20 years or older 4) The patient with a documented informed consent for the participation to this study from their own free will

Exclusion criteria

Exclusion criteria: 1) The case with a history of irradiation to the neck 2) The patient who participated in other clinical trials within three months 3) Allergic history for Sonazoid or Indigo carmine 4) Allergic history for egg 5) A woman with possibility of the pregnancy or the intention, a pregnant woman or lactation 6) The patient in whom a principle investigator or members judged to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Adverse events observed from the injection of Sonazoid until the 30 day after surgery	—

Secondary

Measure	Time frame
1) Detection of SN with contrast-enhanced ultrasonography using Sonazoid as tracer 2) Microvascular count observed in SN using Superb Microvascular Imaging (SMI)	—

Contacts

Public ContactNaohiro WAKISAKA

Kanazawa University Hospital

wakisaka@med.kanazawa-u.ac.jp+81-76-265-2413

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026